Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes false


��' ��	2 380
.LINEAGE CELL THERAPEUTICS, INC
Corporation no: 876343	10834
- - -


	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	08/09/2025
	www.isa.gov.il			www.tase.co.il				Reference:	2025-02-067771	Time of broadcast: 18:14 18:14

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000


	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onLineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes

Lineage_isa.pdf



References of previous documents relating to this matter(the reference does not constitute incorporation by reference):


- - -
Stock Exchange/Market: -1	Date of revision of form structure: 06/08/2024
Address: HARBOR BAY PARKWAY 1301 , ALAMEDA 94502 CALIFORNIA , U.S.A Tel: 5105213390 , Fax: 5105213389
E-mail address: [email protected] Company site: biotimeinc.com

Previous names of reporting entity: .BIOTIME, INC

Name of the Signatory: Gerzi SHNEOR Ilan Position of Signatory in the reporting corporation: Legal Adviser Name of Employer Company: PEARL COHEN ZEDEK LATZER BARATZ
Address: Derech Menachem Begin 121 , Tel Aviv 6701203 Telephone: 03-3039000 Facsimile: E-mail: [email protected] 1
U.S.A

AI Terminal